"Analysts Laud Viking Therapeutics' Soaring Stock on Positive Weight-Loss Drug Data"
TL;DR Summary
Viking Therapeutics stock surged by 25% after announcing positive results from a phase 1 clinical study of its oral obesity drug VK2735, showing up to 3.3% placebo-adjusted mean weight loss and promising safety and tolerability. The company plans to advance the oral and injectable formulations of the drug into further testing, with expectations for strong pipeline prospects, making it a potential buy for aggressive investors.
- Why Viking Therapeutics Stock Is Skyrocketing Today Yahoo Finance
- Eli Lilly Stock Jumps Entry Point As Weight-Loss Drugs Fervor Heats Up Investor's Business Daily
- UBS sends a wake-up call to take profits on an outperforming stock. We're heeding it CNBC
- Viking Therapeutics stock rises on positive oral obesity drug Phase 1 data Yahoo Finance
- Viking Therapeutics’ oral weight-loss drug results lauded by analysts MarketWatch
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
85%
427 → 65 words
Want the full story? Read the original article
Read on Yahoo Finance